🚀 VC round data is live in beta, check it out!
Structure Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Structure Therapeutics and similar public comparables like Hualan Biological Engineering, Indivior Pharmaceuticals, Amoytop Biotech, ACADIA Pharmaceuticals and more.
Structure Therapeutics Overview
About Structure Therapeutics
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Founded
2019
HQ
Employees
163
Website
Sectors
Financials (LTM)
EV
$2B
Structure Therapeutics Financials
Structure Therapeutics reported last 12-month revenue of $2M and negative EBITDA of ($308M).
In the same LTM period, Structure Therapeutics generated $2M in gross profit, ($308M) in EBITDA losses, and had net loss of ($184M).
Revenue (LTM)
Structure Therapeutics P&L
In the most recent fiscal year, Structure Therapeutics reported revenue of — and EBITDA of ($185M).
Structure Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $2M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($308M) | XXX | ($185M) | XXX | XXX | XXX |
| EBITDA Margin | (16877%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (12183%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($184M) | XXX | ($141M) | XXX | XXX | XXX |
| Net Margin | (10050%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Structure Therapeutics Stock Performance
Structure Therapeutics has current market cap of $4B, and enterprise value of $2B.
Market Cap Evolution
Structure Therapeutics' stock price is $55.20.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $4B | 3.6% | XXX | XXX | XXX | $-1.99 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialStructure Therapeutics Valuation Multiples
Structure Therapeutics trades at 1352.7x EV/Revenue multiple, and (8.0x) EV/EBITDA.
EV / Revenue (LTM)
Structure Therapeutics Financial Valuation Multiples
As of April 11, 2026, Structure Therapeutics has market cap of $4B and EV of $2B.
Equity research analysts estimate Structure Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Structure Therapeutics has a P/E ratio of (21.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 1352.7x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (8.0x) | XXX | (13.3x) | XXX | XXX | XXX |
| EV/EBIT | (11.1x) | XXX | (14.0x) | XXX | XXX | XXX |
| EV/Gross Profit | 1352.7x | XXX | — | XXX | XXX | XXX |
| P/E | (21.3x) | XXX | (27.7x) | XXX | XXX | XXX |
| EV/FCF | (4.0x) | XXX | (10.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Structure Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Structure Therapeutics Margins & Growth Rates
Structure Therapeutics' revenue in the last 12 month grew by 166%.
Structure Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.1M for the same period.
Structure Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 166% | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | (16877%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | 99% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3503% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13467% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Structure Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Hualan Biological Engineering | XXX | XXX | XXX | XXX | XXX | XXX |
| Indivior Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Amoytop Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| ACADIA Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Santen Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Structure Therapeutics M&A Activity
Structure Therapeutics acquired XXX companies to date.
Last acquisition by Structure Therapeutics was on XXXXXXXX, XXXXX. Structure Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Structure Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialStructure Therapeutics Investment Activity
Structure Therapeutics invested in XXX companies to date.
Structure Therapeutics made its latest investment on XXXXXXXX, XXXXX. Structure Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Structure Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Structure Therapeutics
| When was Structure Therapeutics founded? | Structure Therapeutics was founded in 2019. |
| Where is Structure Therapeutics headquartered? | Structure Therapeutics is headquartered in United States. |
| How many employees does Structure Therapeutics have? | As of today, Structure Therapeutics has over 163 employees. |
| Who is the CEO of Structure Therapeutics? | Structure Therapeutics' CEO is Professor Raymond C. Stevens. |
| Is Structure Therapeutics publicly listed? | Yes, Structure Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Structure Therapeutics? | Structure Therapeutics trades under GPCR ticker. |
| When did Structure Therapeutics go public? | Structure Therapeutics went public in 2023. |
| Who are competitors of Structure Therapeutics? | Structure Therapeutics main competitors are Hualan Biological Engineering, Indivior Pharmaceuticals, Amoytop Biotech, ACADIA Pharmaceuticals. |
| What is the current market cap of Structure Therapeutics? | Structure Therapeutics' current market cap is $4B. |
| What is the current revenue of Structure Therapeutics? | Structure Therapeutics' last 12 months revenue is $2M. |
| What is the current revenue growth of Structure Therapeutics? | Structure Therapeutics revenue growth (NTM/LTM) is 166%. |
| What is the current EV/Revenue multiple of Structure Therapeutics? | Current revenue multiple of Structure Therapeutics is 1352.7x. |
| Is Structure Therapeutics profitable? | No, Structure Therapeutics is not profitable. |
| What is the current EBITDA of Structure Therapeutics? | Structure Therapeutics has negative EBITDA and is not profitable. |
| What is Structure Therapeutics' EBITDA margin? | Structure Therapeutics' last 12 months EBITDA margin is (16877%). |
| What is the current EV/EBITDA multiple of Structure Therapeutics? | Current EBITDA multiple of Structure Therapeutics is (8.0x). |
| What is the current FCF of Structure Therapeutics? | Structure Therapeutics' last 12 months FCF is ($619M). |
| What is Structure Therapeutics' FCF margin? | Structure Therapeutics' last 12 months FCF margin is (33901%). |
| What is the current EV/FCF multiple of Structure Therapeutics? | Current FCF multiple of Structure Therapeutics is (4.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.